Systèmes d’administration de médicaments à libération modifiée: Biodisponibilité

Modified-release formulations have bioavailability below 100% due to incomplete drug release, prolonged absorption phases, and first-pass metabolism in orally administered drugs. Additionally, limitations in drug permeability across the gastrointestinal epithelium restrict the fraction of drug reaching systemic circulation, reducing overall bioavailability compared to conventional formulations.

Dose dumping refers to the unintended rapid release of drug that could lead to toxicity. Single-dose studies evaluate absorption profiles and detect dose dumping risk by measuring maximum plasma concentration (Cmax), time to reach Cmax (tmax), and area under the concentration-time curve (AUC), which reflects total drug exposure.

Multiple-dose studies assess the formulation's ability to maintain sustained therapeutic levels over extended periods, determining steady-state plasma concentrations where drug administration rate equals elimination rate. They evaluate steady-state concentration ratios and percentage fluctuation to minimize peaks and troughs, reducing side effects and enhancing therapeutic efficacy.

In vitro bioequivalence tests simulate gastrointestinal conditions using biorelevant dissolution media that account for pH variations, fed versus fasted states, and the presence of bile or pancreatic secretions. These assessments predict in vivo performance and ensure formulations meet regulatory bioequivalence criteria before advancing to clinical testing.

Modified-release formulations are compared to reference standards such as oral solutions, suspensions, or existing modified-release products with well-established pharmacokinetics. Immediate-release formulations serve as primary reference standards for evaluating modified-release products. These comparisons ensure consistent bioavailability and therapeutic performance across formulations.

In vivo bioavailability studies measure the effects of food and circadian rhythms on drug absorption in modified-release formulations. These factors influence gastrointestinal pH, transit time, and digestive secretion levels, which can alter drug release profiles and absorption rates, affecting therapeutic outcomes and plasma concentration fluctuations.

Integrating in vivo bioavailability studies with in vitro bioequivalence assessments enables researchers to optimize modified-release formulations for consistent drug release and improved therapeutic outcomes. In vitro tests predict in vivo performance, while in vivo studies confirm actual bioavailability, minimizing variability in patient response and ensuring regulatory compliance.